Exact Sciences Corp at Jefferies Heathcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Tycho Peterson - Jefferies - Analyst : No, no, it's great. We're halfway through and that was only the first question. So makes my job easy. So a couple of things to think about. I guess if we think about your data readout in October, is there kind of a threshold that we should be thinking about? And would you kind of pull the plug on it if it doesn't kind of -- REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 05, 2024 / 3:00PM, EXAS.OQ - Exact Sciences Corp at Jefferies Heathcare Conference

Question: Tycho Peterson - Jefferies - Analyst : I guess thinking a little bit about like recent AdCom seem fairly down the middle didn't seems like there's any surprises. I'd love your take on that. And then as we think about maybe the labelling on shield them particular, like if they come out first line with very restrictive label, maybe not applicable to AA, not applicable to asymptomatic patients. What do you think that does to the market? And does that change your strategy?

Question: Tycho Peterson - Jefferies - Analyst : I guess if the data in October is good, can you help us think about the roadmap from there, timeline for approvals, investments you may need to make.

Question: Tycho Peterson - Jefferies - Analyst : Can you just make a comment or two on Geneoscopy because they're out talking to people and making noise and just curious what your response is to that. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 05, 2024 / 3:00PM, EXAS.OQ - Exact Sciences Corp at Jefferies Heathcare Conference

Question: Tycho Peterson - Jefferies - Analyst : Let's talk about sales and marketing. It was a big focus, obviously, on your first quarter call. Can you talk about when you decided to kind of pull the trigger, high additional reps, I think they've been in the field two, three weeks now, just talk a little about early traction and importantly, we committed to kind of profitability going forward and --

Question: Tycho Peterson - Jefferies - Analyst : But they're [resments] are very targeted. I think they've been very clear, first of all, your sales force is going to be 7 times, 8 times the size, but they talked about kind of going after high Medicare population, maybe states with the ACS guidelines. So how do you think about that vis a vis you have a much larger channel, larger sales force you have to counter detailed, you have to pivot.

Question: Tycho Peterson - Jefferies - Analyst : And sticking with sales for a minute. You've got a couple of upcoming launches, MRD and Cologuard 2.0. I guess anything different about the sales channel as you kind of think about those products coming to market, are those tests coming to market in '25?

Question: Tycho Peterson - Jefferies - Analyst : You also increased the price. So how do you think about that, first higher price tests in 10 years for Cologuard. So how do you think about that? I think you said 50% of docs say the orders. So it doesn't seem like it's a hindrance, but --

Question: Tycho Peterson - Jefferies - Analyst : Maybe the last couple of seconds here, just message around capital deployment and M&A, right? So you've been consolidating some of the industry with Genomic Health. I'm just curious, there's a lot of dislocation in the market. How do you think about the M&A landscape over the next couple of years?

Question: Tycho Peterson - Jefferies - Analyst : Great. Good to see you, Kevin.